Browse the evidence

Consumption of specific soluble dietary fibers (psyllium, oat beta-glucan) significantly reduces serum apolipoprotein B (ApoB) levels, whereas other soluble fibers (konjac glucomannan) may have no significant effect.

To lower your ApoB and heart disease risk, prioritize specific soluble fibers like psyllium husk or oat beta-glucan. General fiber intake is important, but the source matters: studies show psyllium significantly lowers ApoB, while other fibers like konjac may not have the same effect. Aim for 8-15 grams of these specific fibers daily, ideally alongside a balanced diet.

Higher levels of the satiety hormone leptin are associated with lower salt taste preference during both low-carbohydrate and low-fat diets.

Your body's satiety hormone, leptin, appears to influence how much you prefer salty foods. Higher leptin levels are linked to a lower preference for salt, regardless of whether you are eating low-carb or low-fat. This suggests a biological link between fullness signals and taste preferences.

Maintaining Hemoglobin A1c (HbA1c) levels below 6.0% is a critical intervention for preventing the onset and progression of coronary atherosclerotic heart disease (CHD).

To lower your risk of heart disease, aim to keep your HbA1c below 6%. This involves eating a healthy diet, reducing calories if overweight, and getting at least 150 minutes of moderate exercise per week. Regular screening is essential to catch prediabetes early.

GLP-1 receptor agonists (semaglutide, tirzepatide) cause rapid, significant loss of facial and body subcutaneous fat, leading to skin laxity, volume loss, and accelerated facial aging that requires proactive, multimodal aesthetic intervention.

If you are taking Ozempic or Mounjaro, expect your face to lose volume and your skin to sag. Don't wait until you look 'old' to act. Start aesthetic treatments (like fillers or skin tightening) early in your weight loss journey to maintain your shape and youthfulness.

A structured, multimodal aesthetic intervention protocol (fillers, RF, HIFU, collagen stimulators) initiated early in GLP-1 therapy mitigates facial volume loss and skin laxity.

Work with a cosmetologist to create a personalized plan. Use fillers for volume, RF/HIFU for tightening, and collagen stimulators for skin quality. Start early, not after you've lost all the weight.

GLP-1 receptor agonists (e.g., semaglutide) can support sustained weight stability and may be safely restarted postoperatively in body contouring patients.

If you are using GLP-1 agonists like semaglutide for weight loss, discuss with your doctor whether it is safe to restart or continue them after body contouring surgery. They can help maintain your weight stability and support long-term results.

Adding Subetta® (affinity-purified antibodies against the insulin receptor beta-subunit) and cholecalciferol (Vitamin D) to standard therapy significantly improves glycemic control, lipid profiles, and reduces body mass index in elderly women with type 2 diabetes compared to standard therapy alone.

For elderly women with Type 2 Diabetes who are struggling with weight gain and high blood sugar despite standard medication, adding Vitamin D (4000 IU daily after a loading phase) and Subetta® to their existing regimen (Metformin/Gliclazide) can significantly improve blood sugar, cholesterol, and weight loss without causing dangerous low blood sugar episodes.

Early intensive intervention targeting stringent glycaemic control (HbA1c ≤ 6.5%) and significant weight loss (≥10%) at diagnosis improves long-term prognosis and prevents microvascular complications in younger patients with longer life expectancy.

If you are diagnosed with Type 2 Diabetes and are under 65, do not accept a standard HbA1c target of 7% as the end goal. Work with your doctor to aim for a stricter target (≤ 6.5%) and significant weight loss (10% or more) immediately. This early, intensive approach is critical for preventing long-term complications like eye and kidney damage, especially given your longer life expectancy.

GLP-1 receptor agonists (GLP-1 RA) and SGLT2 inhibitors are preferred first-line treatments for patients with Type 2 Diabetes and obesity or cardiovascular disease, respectively, due to their weight-reducing and cardioprotective properties.

If you have Type 2 Diabetes and obesity or heart disease, ask your doctor about GLP-1 receptor agonists or SGLT2 inhibitors. These drugs not only help control blood sugar but also promote weight loss and protect your heart, making them preferred choices over metformin alone for many patients.

Younger participants (under 51 years) experience significantly greater weight loss from the same intervention compared to older participants (over 51 years).

If you are over 50, the standard 1500-1800 calorie/30-min aerobic plan may not yield significant weight loss on its own. You may need to adjust expectations, consult your provider for age-specific strategies (like adding strength training), and focus on health markers beyond just the scale.

Adding luseogliflozin (an SGLT2 inhibitor) to incretin modulator therapy produces an additive glucose-lowering effect, specifically reducing time above range, with the magnitude of benefit being significantly greater in patients consuming high-carbohydrate diets compared to low-carbohydrate diets.

If you are taking an incretin-based diabetes medication (like a GLP-1 agonist or DPP4 inhibitor) and consume a diet high in carbohydrates (e.g., >180g carbs daily), adding luseogliflozin (2.5mg daily) may provide better blood sugar control than adding it to a low-carb diet. This combination appears to work additively, meaning the drugs complement each other to handle the glucose load from carbs more effectively than either might alone in that specific context.

Moderate alcohol consumption may confer cardiovascular protection in Type 2 Diabetes patients, but chronic consumption (even low/moderate) may trigger or worsen T2DM and raise blood pressure.

The effect of alcohol on diabetes is mixed. While moderate drinking might lower heart disease risk, it can also raise blood pressure and worsen diabetes. If you drink, do so in moderation. If you have uncontrolled diabetes or high blood pressure, it may be safer to avoid alcohol. Consult your doctor.

Intermittent fasting improves glycemic control in patients with Type 2 Diabetes, including reductions in fasting glucose, HbA1c, and insulin levels, though it carries a risk of hypoglycemia requiring medication adjustment.

If you have Type 2 Diabetes, intermittent fasting can improve your blood sugar control, but you must work with your doctor to adjust medications like insulin or sulfonylureas to avoid low blood sugar. Studies show that with proper management, IF is safe and can lower HbA1c and fasting glucose levels without severe adverse events.

The improvement in arterial stiffness (PWV) resulting from weight loss is correlated with the reduction in systolic and diastolic blood pressure, suggesting blood pressure changes may mediate this benefit.

When you lose weight, your blood pressure likely drops, and this drop is closely linked to the improvement in your arterial stiffness. Monitoring both weight and blood pressure gives you a better understanding of your cardiovascular health improvements.

A remotely delivered, 12-month GLP-1RA (semaglutide) supported weight management program achieves significant weight loss (mean 19.1% of starting weight) in participants who maintain an active subscription, but high withdrawal rates (60.4%) limit generalizability.

If you have obesity and are considering a GLP-1RA like semaglutide, a remote program can help you lose significant weight (around 19% on average) if you stick with it. However, be aware that many people drop out, often due to side effects or cost. To succeed, you need to be committed to the weekly injections and the digital support, and understand that stopping the medication likely leads to weight regain.

Tirzepatide produces significantly greater long-term total body weight loss and fat mass reduction compared to Semaglutide in real-world clinical practice, with effects becoming distinct after 6 months.

If you are choosing between Semaglutide and Tirzepatide for long-term weight management, Tirzepatide offers significantly greater weight loss after 12 months. To maximize results and protect your muscle, you must combine the medication with a program that includes strength training twice a week and a protein intake of 60-90 grams daily.

Females experience significantly greater weight loss than males when treated with incretin-based obesity medications (Semaglutide and Tirzepatide).

If you are male, expect that your weight loss may be slower than that of female peers taking the same medication. This is a known biological response. Do not be discouraged; the medication still provides significant metabolic benefits and fat loss, even if the scale moves slower.

Orlistat treatment for 3 months in women with PCOS produces a statistically significant reduction in body weight and serum testosterone levels, with weight loss effects being greater than those observed with metformin.

If you have PCOS and are looking to lose weight and lower testosterone, Orlistat (120mg, 3x daily) may be more effective for weight loss than Metformin over a short 3-month period, while still effectively lowering testosterone. Ensure you follow the dietary changes recommended during the initial 8-week period to maximize results and minimize side effects.

High supplemental intake of vitamin D (≥800 IU/day) and calcium (≥1,200 mg/day) is associated with a significantly lower risk of developing type 2 diabetes in women, with the combined high intake reducing risk by 33% compared to low intake.

For women looking to potentially lower their risk of type 2 diabetes, aiming for high intakes of Vitamin D and Calcium via supplements may be beneficial. Specifically, targeting at least 800 IU of Vitamin D and 1,200 mg of Calcium daily was associated with a 33% lower risk in this study. Note that this benefit was observed with supplements, not just dietary sources, and the study focused on women.

Supplemental Vitamin D intake (≥400 IU/day) is associated with a lower risk of type 2 diabetes, whereas total or dietary Vitamin D intake is not significantly associated after adjusting for other dietary factors.

If you are a woman, taking a Vitamin D supplement providing at least 400 IU daily may be associated with a modestly lower risk of type 2 diabetes compared to not taking such supplements. However, simply eating Vitamin D-rich foods may not provide the same protective association in this study.

High supplemental Calcium intake (≥500 mg/day) is associated with a lower risk of type 2 diabetes, whereas dietary Calcium intake is not significantly associated after multivariate adjustment.

If you are a woman, taking a Calcium supplement providing at least 500 mg daily may be associated with a modestly lower risk of type 2 diabetes compared to not taking such supplements. However, simply eating Calcium-rich foods may not provide the same protective association in this study.

Dietary phytoestrogens (specifically isoflavones from soy and lignans from flax) may confer health benefits for cardiovascular disease, cancer, osteoporosis, and menopausal symptoms through both estrogen-receptor-dependent and independent mechanisms.

Incorporate soy (tofu, tempeh, soy milk) and flaxseed into your diet. While clinical results on cholesterol vary, the mechanistic and epidemiological evidence suggests these foods may support heart health and hormonal balance, especially for postmenopausal women. Note that individual gut bacteria determine how effectively you process these compounds.

Soy protein containing phytoestrogens may lower LDL cholesterol and improve lipid profiles in hypercholesterolemic individuals, primarily through up-regulation of LDL receptors.

If you have high cholesterol, adding soy protein to your diet may help lower LDL levels, though results vary. It is not a magic bullet, but a supportive dietary strategy.

Consumption of high-glycemic index (GI) meals induces rapid glucose absorption, leading to hyperinsulinemia and suppressed glucagon, which lowers circulating metabolic fuels (glucose and fatty acids) and triggers compensatory overeating in obese subjects.

For obese individuals, choosing high-glycemic foods (like instant oatmeal or white bread) over low-glycemic options (like steel-cut oats or legumes) can trigger a hormonal response that lowers blood fuel levels and increases hunger, leading to significantly higher calorie consumption later in the day, even if the initial meal size is the same. Prioritize food structure and glycemic index to manage appetite.